Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B

Published:2023-07-24 Issue:15 Volume:66 Page:10694-10714
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Deau Emmanuel¹,Lindberg Mattias F.¹^ORCID,Miege Frédéric²,Roche Didier²,George Nicolas³,George Pascal¹,Krämer Andreas⁴⁵,Knapp Stefan⁴^ORCID,Meijer Laurent¹^ORCID

Affiliation:

1. Perha Pharmaceuticals, Perharidy, 29680 Roscoff, France

2. Edelris, Bâtiment Bioserra 1, 60 Avenue Rockefeller, 69008 Lyon, France

3. Oncodesign, 25-27 Avenue du Québec, 91140 Villebon-sur-Yvette, France

4. Goethe-University Frankfurt, Structural Genomics Consortium (SGC), Buchmann Institute for Molecular Life Sciences, Max-von Laue Str. 15, 60438 Frankfurt am Main, Germany

5. Goethe-University Frankfurt, Institute of Pharmaceutical Chemistry, Max-von Laue Str. 9, 60438 Frankfurt am Main, Germany

Funder

Agence Nationale de la Recherche

Deutsches Krebsforschungszentrum

Eurostars

Fonds Unique Interminist?riel

Bpifrance

Structural Genomics Consortium

H2020 Health

Horizon 2020 Framework Programme

Fondation J?r?me Lejeune

Frankfurt Cancer Institute

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00884

Reference86 articles.

1. DYRK1A and cognition: A lifelong relationship

2. Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview

3. An overview of cdc2‐like kinase 1 (Clk1) inhibitors and their therapeutic indications

4. DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease

5. DYRK1A inhibitors for disease therapy: Current status and perspectives

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer’s Disease;Journal of Medicinal Chemistry;2024-07-23

2. Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome;Science Translational Medicine;2024-01-24

3. Originally Designed Dyrk1a Inhibitors as Potent Dyrk1a/Clk1/Clk4/Haspin Multiple Inhibitors: Synthesis and Biological Activities of Sulfur-Containing Tetracycles;2024

4. Chemical, Biochemical, Cellular, and Physiological Characterization of Leucettinib-21, a Down Syndrome and Alzheimer’s Disease Drug Candidate;Journal of Medicinal Chemistry;2023-12-05

5. Interneuron migration defects during corticogenesis contribute toDyrk1ahaploinsufficiency syndrome pathogenesis via actomyosin dynamics deregulations;2023-11-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3